The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

被引：0

作者：

Mutlu Hizal

Burak Bilgin

Nail Paksoy

Özgür Açıkgöz

Ahmet Sezer

Mustafa Gürbüz

Naziye Ak

Şebnem Yücel

Murat Ayhan

Cihan Erol

Aykut Demirkıran

Nil Molinas Mandel

Abdallah Shbair

İvo Gökmen

Tuğba Başoğlu

Semra Paydaş

Atike Gökçen Demiray

Yakup İriağaç

Teoman Şakalar

Esra Zeynelgil

Ali Murat Tatlı

Aykut Bahçeci

Deniz Can Güven

Burcu Caner

Alper Can

Ahmet Gülmez

Yusuf Karakaş

Bülent Yalçın

Ahmet Demirkazık

Ahmet Bilici

Adnan Aydıner

Perran Fulden Yumuk

Mehmet Ali Nahit Şendur

机构：

[1] Ankara City Hospital,Department of Medical Oncology

[2] Atatürk Chest Disease and Chest Surgery Research and Education Hospital,Department of Medical Oncology

[3] İstanbul University, Department of Medical Oncology, İstanbul Faculty of Medicine

[4] Medipol University,Department of Medical Oncology

[5] Faculty of Medicine,Department of Medical Oncology

[6] Başkent University,Department of Medical Oncology

[7] Faculty of Medicine,Department of Medical Oncology

[8] Ankara University,Department of Medical Oncology

[9] Faculty of Medicine,Department of Medical Oncology

[10] Yozgat City Hospital,Department of Medical Oncology, Meram Faculty of Medicine

[11] Kartal Lütfi Kırdar City Hospital,Department of Medical Oncology

[12] Yıldırım Beyazıt University Faculty of Medicine,Department of Medical Oncology

[13] Necmeddin Erbakan University,Department of Medical Oncology, Faculty of Medicine

[14] American Hospital,Division of Medical Oncology

[15] Bezmialem University Faculty of Medicine,Department of Medical Oncology

[16] Trakya University,Department of Medical Oncology

[17] Marmara University School of Medicine,Department of Medical Oncology

[18] Çukurova University Faculty of Medicine,Department of Medical Oncology

[19] Pamukkale University Faculty of Medicine,Department of Medical Oncology

[20] Namık Kemal University Faculty of Medicine,Department of Medical Oncology

[21] Necip Fazıl City Hospital,Department of Medical Oncology

[22] Dışkapı Education and Research Hospital,Department of Medical Oncology

[23] Akdeniz University Faculty of Medicine,Department of Medical Oncology

[24] Ersin Arslan Education and Research Hospital,Department of Medical Oncology

[25] Hacettepe University Faculty of Medicine,Department of Medical Oncology

[26] Uludağ University Faculty of Medicine,Department of Medical Oncology

[27] İstinye University Faculty of Medicine,undefined

[28] İnönü University Faculty of Medicine,undefined

[29] Bodrum Acıbadem Hospital,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2022年 / 148卷

关键词：

Osimertinib; Non-small cell lung cancer; EGFR; T790M; Second line;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1501 / 1508

页数：7

共 50 条

[31] Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer
Lamb, Yvette N.
Scott, Lesley J.
TARGETED ONCOLOGY, 2017, 12 (04) : 555 - 562
[32] Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer
Yvette N. Lamb
Lesley J. Scott
Targeted Oncology, 2017, 12 : 555 - 562
[33] EGFR T790M resistance mutation in NSCLC: Real-life data of patients treated with osimertinib.
Hochmair, Maximilian J.
Holzer, Sophia
Filipits, Martin
Mohn-Staudner, Andrea
Arns, Madeleine
Errhalt, Peter
Absenger, Gudrun
Koller-Herzog, Ursula
Setinek, Ulrike
Haslbauer, Ferdinand
Korger, Mark A.
Patocka, Kurt
Kolb, Rainer
Burghuber, Otto
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[34] EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib
Hochmair, Maximilian
Holzer, Sophia
Filipits, Martin
Mohn-Staudner, Andrea
Errhalt, Peter
Absenger, Gudrun
Bundalo, Tatjana
Arns, Madeleine
Setinek, Ulrike
Mikes, Romana
Kolb, Rainer
Schumacher, Michael
Zoechbauer-Mueller, Sabine
Patocka, Kurt
Haslbauer, Ferdinand
Rudzki, Jakob
Burghuber, Otto
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1254
[35] ASTRIS global real world study of osimertinib in patients (pts) with EGFR T790M non-small cell lung cancer (NSCLC): Subpopulation analyses
Provencio, M.
Cheema, P. K.
Vansteenkiste, J. F.
Cho, B. C.
Zhou, C.
Yu, J.
Martin, C.
Park, K.
He, Y.
Hu, Y.
Vicente, D.
Miranda, M.
Rigas, J.
de Marinis, F.
ANNALS OF ONCOLOGY, 2018, 29
[36] Risk Factors for Developing T790M Mutation in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Ouyang, W.
Xie, C.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E526 - E526
[37] Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer
Stratmann, Jan A.
Michels, Sebastian
Hornetz, Sofia
Christoph, Daniel C.
Sackmann, Sandra
Spengler, Werner
Bischoff, Helge
Schaefer, Monica
Alt, Juergen
Mueller, Annette
Laack, Eckart
Kimmich, Martin
Griesinger, Frank
Sebastian, Martin
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (12) : 2457 - 2463
[38] Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer
Jan A. Stratmann
Sebastian Michels
Sofia Hornetz
Daniel C. Christoph
Sandra Sackmann
Werner Spengler
Helge Bischoff
Monica Schäfer
Jürgen Alt
Annette Müller
Eckart Laack
Martin Kimmich
Frank Griesinger
Martin Sebastian
Journal of Cancer Research and Clinical Oncology, 2018, 144 : 2457 - 2463
[39] EGFR T790M resistance mutation in NSCLC: Real-life data of Austrian patients treated with osimertinib
Holzer, Sophia
Hochmair, Maximilian
Filipits, Martin
Mohn-Staudner, Andrea
Errhalt, Peter
Absenger, Gudrun
Bundalo, Tatjana
Arns, Britt-Madelaine
Setinek, Ulrike
Mikes, Romana
Kolb, Rainer
Schumacher, Michael
Zoechbauer-Mueller, Sabine
Patocka, Kurt
Haslbauer, Ferdinand
Rudzki, Jakob
Burghuber, Otto Chris
WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 (19-20) : 769 - 770
[40] Osimertinib in patients with T790M mutation positive advanced non-small cell lung cancer (NSCLC): Korean subgroup analysis from pooled phase II data
Ahn, M-J
Lee, J-S.
Han, J-Y.
Kim, D-W.
Cho, B. C.
Kang, J. H.
Kim, S-W.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →